<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398771</url>
  </required_header>
  <id_info>
    <org_study_id>LG-VROS001</org_study_id>
    <nct_id>NCT04398771</nct_id>
  </id_info>
  <brief_title>To Evaluate Safety and Effectiveness of RovatitanTab.</brief_title>
  <official_title>A Multicenter, Single-arm, Prospective, Observational Study to Evaluate the Safety and Effectiveness of a Fixed-dose Combination Containing Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patient With Hypertension and Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of a fixed-dose combination containing valsartan and
      rosuvastatin (Rovatitan® Tablet) in patient with hypertension and hypercholesterolemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Effectiveness: the ratio of patients who reach target BP or LDL-cholesterol

        -  Safety: we will collect safety data
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The ratio of patients who reach the target BP</measure>
    <time_frame>12weeks</time_frame>
    <description>SBP/DBP&lt;140/90mmHg (&lt;60years), SBP/DBP&lt;150/90mmHg (&gt;=60years)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ratio of patients who reach the target LDLcholesterol</measure>
    <time_frame>12weeks</time_frame>
    <description>target LDL refered to Hyperlipidemia pharmacotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ratio of patients who reach the target BP and LDL-c</measure>
    <time_frame>12weeks</time_frame>
    <description>SBP/DBP&lt;140/90mmHg (&lt;60years), SBP/DBP&lt;150/90mmHg (&gt;=60years), target LDL</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>Rovatitan 5/80mg (Rosuvastatin 5mg/Valsartan 80mg) Rovatitan 5/160mg (Rosuvastatin 5mg/Valsartan 160mg) Rovatitan 10/80mg (Rosuvastatin 10mg/Valsartan 80mg) Rovatitan 10/160mg (Rosuvastatin 10mg/Valsartan 160mg) Rovatitan 20/80mg (Rosuvastatin 20mg/Valsartan 80mg) Rovatitan 20/160mg (Rosuvastatin 20mg/Valsartan 160mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin/Valsartan</intervention_name>
    <description>Rovatitan QD for 12 weeks</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Rovatitan Tab.</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have hypertension and hyperlipidemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have hypertension and hyperlipidemia and older than 19 years

          -  Patients who undertstand purpose and method of study, agree with study

        Exclusion Criteria:

          -  Patients who have been administered Rosuvastatin/Valsartan as a anti-
             hyperlipiddemic/anti-hypertensive drugs

          -  Uncontrolled hypertension (SBP&gt;=180mmHg or DBP&gt;=110mmHg)

          -  Patients who participated another clinical study or observational study 3 months ago.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kang seokmin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>songyi Park</last_name>
    <phone>=82-2-6987-4195</phone>
    <email>songyi-park@lgchem.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

